SEC Form DEF 14A filed by TransCode Therapeutics Inc.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Securities Exchange Act of 1934
Boston, MA 02109
To Be Held on November 22, 2024
Interim Chief Executive Officer and
Chief Financial Officer
To Be Held On November 22, 2024
| | | | | 2 | | | |
| | | | | 8 | | | |
| | | | | 11 | | | |
| | | | | 20 | | | |
| | | | | 21 | | | |
| | | | | 21 | | | |
| | | | | 22 | | | |
| | | | | 23 | | | |
| | | | | A-1 | | |
PROXY STATEMENT
FOR SPECIAL MEETING OF STOCKHOLDERS
To Be Held at 9:30 a.m. Eastern Time on
November 22, 2024
BELOW IS FOR YOUR CONVENIENCE ONLY AND IS MERELY A SUMMARY OF
THE INFORMATION CONTAINED IN THIS PROXY STATEMENT. YOU SHOULD
READ THIS ENTIRE PROXY STATEMENT CAREFULLY.
SOLICIT ADDITIONAL PROXIES IF THERE ARE INSUFFICIENT VOTES AT THE TIME
OF THE SPECIAL MEETING TO APPROVE THE RATIFICATION PROPOSAL OR
THE REVERSE STOCK SPLIT PROPOSAL
Name of Beneficial Owner
|
| |
Shares
Beneficially Owned |
| |
Percentage
of Shares Beneficially Owned |
| ||||||
Named Executive Officers and Directors | | | | | | | | | | | | | |
Thomas A. Fitzgerald, Interim Chief Executive Officer, Chief Financial Officer, Director(1)
|
| | | | 427,228 | | | | | | 2.7% | | |
Philippe Calais, PhD, Director(2)
|
| | | | 51,327 | | | | | | 0.3% | | |
Erik Manting, PhD, Director(3)
|
| | | | 51,167 | | | | | | 0.3% | | |
Magda Marquet, PhD, Director(4)
|
| | | | 51,167 | | | | | | 0.3% | | |
All executive officers and directors as a group (4 persons)
|
| | | | 629,889 | | | | | | 3.6% | | |
TO THE
AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION
OF
TRANSCODE THERAPEUTICS, INC.
Chief Financial Officer